(Q42723108)

5 November 2017

title

Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients (English)

1 reference

5 November 2017

1 reference

dasatinib monohydrate

1 reference

1 reference

1 reference

Naoto Takahashi

1

1 reference

5 November 2017

Masatomo Miura

series ordinal

2

1 reference

5 November 2017

Takenori Niioka

series ordinal

3

1 reference

5 November 2017

Kenichi Sawada

series ordinal

4

1 reference

5 November 2017

publication date

7 December 2011

1 reference

Cancer Chemotherapy and Pharmacology

5 November 2017

published in

1 reference

5 November 2017

volume

69

1 reference

5 November 2017

issue

4

1 reference

5 November 2017

page(s)

999-1004

1 reference

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

5 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Metabolism and disposition of dasatinib after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

How I treat chronic myeloid leukemia in the imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1797-3

10.1007/S00280-011-1797-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

5 November 2017

1006681817

0 references

1 reference